|
|||||
|
|
Challenge study of the pathogen reduction capacity of the THERAFLEX MB‐Plasma technology |
|
| Authors: | S. Reichenberg U. Gravemann C. Sumian A. Seltsam |
| Affiliation: | 1. Maco Pharma International GmbH, Langen, Germany;2. Red Cross Blood Service NSTOB, Institute Springe, Springe, Germany;3. Macopharma S.A., Tourcoing, France |
| Abstract: | |
| Keywords: | bacterial contamination blood safety lipaemic plasma pathogen inactivation methylene blue‐treated plasma |